<!DOCTYPE html>
<html lang="fa">
 <meta content="text/html;charset=utf-8" http-equiv="content-type"/>
 <head>
  <title>
   Treatment protocols for lymphoma
  </title>
  <link href="d/css/1.css" rel="stylesheet"/>
 </head>
 <body>
  <!-- Start Main Menu Area -->
  <br/>
  <br/>
  <br/>
  <br/>
  <div class="container">
   <div class="row">
   </div>
  </div>
  <section class="teacher-area ptb-10">
   <div class="container">
   </div>
   <section class="course-details-area ptb-60">
    <div class="container">
     <div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
      <h1 style="text-align:center">
       Treatment protocols for lymphoma
      </h1>
      <div class="utdArticleSection utdStyle" id="topicContent">
       <div id="topicTitle">
        Treatment protocols for lymphoma
       </div>
       <div class="authorSectionElem">
        <div class="authorsElementsLeft">
         <dl id="topicContributors">
          <dt>
           <span>
           </span>
           Authors:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Jim Natale, PharmD, BCOP
           </a>
          </dd>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Tim Brenner, PharmD, BCOP
           </a>
          </dd>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Shrina Duggal, PharmD, BCOP
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Section Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Andrew Lister, MD, FRCP, FRCPath, FRCR
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Deputy Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Alan G Rosmarin, MD
           </a>
          </dd>
         </dl>
        </div>
        <div class="authorsElementsRight">
         <div id="literatureReviewDate">
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             Literature review current through:
            </span>
            Jan 2024.
           </bdi>
          </div>
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             This topic last updated:
            </span>
            May 04, 2022.
           </bdi>
          </div>
         </div>
        </div>
       </div>
       <div id="topicWhatsNewContainer">
       </div>
       <div id="topicText">
        <p class="headingAnchor" id="H4993771">
         <span class="h1">
          INTRODUCTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         The following material represents a subset of chemotherapy and immunotherapy regimens that are used for the treatment of patients with lymphoma.
         <strong>
          This is
         </strong>
         <strong>
          not an exhaustive list
         </strong>
         ; it includes regimens that are considered by the authors and editors to be commonly used and important for the care of patients with lymphoma. Additional regimens may be added over time, particularly as treatment for lymphoma evolves.
        </p>
        <p>
         This topic review is intended to provide only a listing of chemotherapy and immunotherapy regimens. It does not address the appropriate context for use of these regimens in the care of patients with lymphoma. Clinicians should refer to the individual disease-oriented topic reviews that discuss the use of these protocols in appropriate clinical situations:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/16228.html" rel="external">
          "Initial treatment of limited stage diffuse large B cell lymphoma"
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/4729.html" rel="external">
          "Initial treatment of advanced stage diffuse large B cell lymphoma"
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/4708.html" rel="external">
          "Diffuse large B cell lymphoma (DLBCL): Suspected first relapse or refractory disease in patients who are medically fit"
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/4741.html" rel="external">
          "Initial treatment of stage I follicular lymphoma"
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/83847.html" rel="external">
          "Initial treatment of stage II to IV follicular lymphoma"
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/4755.html" rel="external">
          "Treatment of relapsed or refractory follicular lymphoma"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/4749.html" rel="external">
          "Initial treatment of peripheral T cell lymphoma"
         </a>
         .)
        </p>
        <p>
        </p>
        <p>
         These tables are provided as examples of how to administer these regimens; there may be other acceptable methods. All chemotherapy and immunotherapy regimens must be administered by clinicians who are trained in the use of chemotherapy and immunotherapy. The clinician is expected to use his or her independent medical judgment in the context of individual circumstances to make adjustments, as necessary.
        </p>
        <p class="headingAnchor" id="H4993783">
         <span class="h1">
          REGIMENS
         </span>
        </p>
        <p class="headingAnchor" id="H4994024">
         <span class="h2">
          Rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone with 21 days between cycles (R-CHOP-21)
         </span>
         <span class="headingEndMark">
          —
         </span>
         (
         <a class="graphic graphic_table graphicRef63586" href="/z/d/graphic/63586.html" rel="external">
          table 1
         </a>
         )
        </p>
        <p class="headingAnchor" id="H4994079">
         <span class="h2">
          Rituximab plus ifosfamide, carboplatin, and etoposide (R-ICE)
         </span>
         <span class="headingEndMark">
          —
         </span>
         (
         <a class="graphic graphic_table graphicRef76030" href="/z/d/graphic/76030.html" rel="external">
          table 2
         </a>
         )
        </p>
        <p class="headingAnchor" id="H935886705">
         <span class="h2">
          Cyclophosphamide plus doxorubicin, vincristine, and prednisone with 21 days between cycles (CHOP-21)
         </span>
         <span class="headingEndMark">
          —
         </span>
         (
         <a class="graphic graphic_table graphicRef81762" href="/z/d/graphic/81762.html" rel="external">
          table 3
         </a>
         )
        </p>
        <p class="headingAnchor" id="H935886730">
         <span class="h2">
          Doxorubicin plus bleomycin, vinblastine, and dacarbazine (ABVD)
         </span>
         <span class="headingEndMark">
          —
         </span>
         (
         <a class="graphic graphic_table graphicRef68131" href="/z/d/graphic/68131.html" rel="external">
          table 4
         </a>
         )
        </p>
        <p class="headingAnchor" id="H4149304156">
         <span class="h2">
          Bendamustine plus rituximab (BR)
         </span>
         <span class="headingEndMark">
          —
         </span>
         (
         <a class="graphic graphic_table graphicRef111141" href="/z/d/graphic/111141.html" rel="external">
          table 5
         </a>
         )
        </p>
        <p class="headingAnchor" id="H546943109">
         <span class="h2">
          Fludarabine plus rituximab (FR)
         </span>
         <span class="headingEndMark">
          —
         </span>
         (
         <a class="graphic graphic_table graphicRef86798" href="/z/d/graphic/86798.html" rel="external">
          table 6
         </a>
         )
        </p>
        <p class="headingAnchor" id="H546943159">
         <span class="h2">
          Fludarabine, cyclophosphamide, and rituximab (FCR)
         </span>
         <span class="headingEndMark">
          —
         </span>
         (
         <a class="graphic graphic_table graphicRef86797" href="/z/d/graphic/86797.html" rel="external">
          table 7
         </a>
         )
        </p>
        <p class="headingAnchor" id="H21931978">
         <span class="h2">
          Dose-adjusted etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin, and rituximab (daEPOCH-R)
         </span>
         <span class="headingEndMark">
          —
         </span>
         (
         <a class="graphic graphic_table graphicRef88411" href="/z/d/graphic/88411.html" rel="external">
          table 8
         </a>
         )
        </p>
        <p class="headingAnchor" id="H227018357">
         <span class="h2">
          Dose-adjusted etoposide, prednisone, vincristine, cyclophosphamide, and doxorubicin (daEPOCH)
         </span>
         <span class="headingEndMark">
          —
         </span>
         (
         <a class="graphic graphic_table graphicRef105216" href="/z/d/graphic/105216.html" rel="external">
          table 9
         </a>
         )
        </p>
        <p class="headingAnchor" id="H2424911585">
         <span class="h2">
          Pembrolizumab monotherapy
         </span>
         <span class="headingEndMark">
          —
         </span>
         (
         <a class="graphic graphic_table graphicRef127101" href="/z/d/graphic/127101.html" rel="external">
          table 10
         </a>
         )
        </p>
        <p class="headingAnchor" id="H2338716601">
         <span class="h1">
          ACKNOWLEDGMENT
         </span>
         <span class="headingEndMark">
          —
         </span>
         The UpToDate editorial staff acknowledges Scott M Wirth, PharmD, BCOP, who contributed to an earlier version of this topic review.
        </p>
       </div>
       <div id="topicVersionRevision">
        Topic 85686 Version 24.0
       </div>
      </div>
     </div>
    </div>
   </section>
  </section>
  <!-- End Main Menu Area -->
  <!-- Start Search Popup Area -->
  <!-- End Footer Area -->
  <!-- Back to top -->
  <a class="scrolltop" href="#top">
   <i class="icofont-hand-drawn-up">
   </i>
  </a>
  <!-- End Back to top -->
  <!-- jQuery Min JS -->
  <!-- Prpper JS -->
  <!-- Bootstrap Min JS -->
  <!-- Classy Nav Min Js -->
  <!-- Owl Carousel Min Js -->
  <!-- Magnific Popup JS -->
  <!-- CounterUp JS -->
  <!-- Waypoints JS -->
  <!-- Form Validator Min JS -->
  <!-- Contact Form Min JS -->
  <!-- Main JS -->
  <!-- Global site tag (gtag.js) - Google Analytics -->
 </body>
</html>
